Application of Alive Collagen supplement in genitourinary menopausal syndrome
- Authors: Bakhtiyarov K.R.1, Kuzmina P.I.1, Cherkashina A.V.1
-
Affiliations:
- I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
- Issue: No 1 (2024)
- Pages: 123-128
- Section: Exchange of Experience
- URL: https://journal-vniispk.ru/0300-9092/article/view/275239
- DOI: https://doi.org/10.18565/aig.2023.289
- ID: 275239
Cite item
Open Access
Access granted
Subscription Access
Abstract
Objective: To evaluate the efficacy and safety of Alive Collagen in postmenopausal women with genitourinary menopausal syndrome (GMS).
Materials and methods: This was a single-center, uncontrolled before-after study. Twenty-five women aged 50–68 years (mean age is 59.44±5.39 years) diagnosed with postmenopausal atrophic vaginitis were examined at the Family Clinic from April to June 2023. The efficacy of taking Alive Collagen at a dosage of 15 g/day for 12 weeks was evaluated. The analysis was carried out using a questionnaire with calculation of the Female Sexual Function Index (FSFI) and visual analog scale developed by R. Nappi.
Results: The postmenopausal period lasted 7±2.40 years, the duration of GMS symptoms ranged from 2 to 10 years (mean period is 5.44±2.63 years). In 12 weeks after taking Alive Collagen, the women noticed a decrease in the symptoms of GMS, namely, itching, burning, and vaginal dryness; a decrease in the severity of dyspareunia was also revealed. FSFI increased from 15.36±4.33 before therapy to 21.58±3.94 after collagen supplementation for 12 weeks. No adverse side effects were detected.
Conclusion: The patients suffering from various symptoms of GMS and having contraindications to menopausal hormone therapy can have a possible alternative to improve their quality of life by taking Alive Collagen supplement at a dose of 15 g/day 30 minutes before meals for 12 weeks.
Full Text
##article.viewOnOriginalSite##About the authors
Kamil R. Bakhtiyarov
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Author for correspondence.
Email: doctorbah@mail.ru
ORCID iD: 0000-0001-7114-4050
Dr. Med. Sci., Professor, Sechenov First Moscow State Medical University
Russian Federation, 119991, Moscow, Trubetskaya str., 8-2Polina I. Kuzmina
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Email: kuzmina_p_i@student.sechenov.ru
ORCID iD: 0009-0004-0098-1774
Student of the Institute of Clinical Medicine named after N.V. Sklifosovsky
Russian Federation, 119991, Moscow, Trubetskaya str., 8-2Anna V. Cherkashina
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Email: cherkashina_a_v@student.sechenov.ru
ORCID iD: 0000-0002-3840-1948
Student of the Institute of Clinical Medicine named after N.V. Sklifosovsky
Russian Federation, 119991, Moscow, Trubetskaya str., 8-2References
- Kagan R., Kellogg-Spadt S., Parish S.J. Practical treatment considerations in the management of genitourinary syndrome of menopause. Drugs Aging. 2019; 36(10): 897-908. https://dx.doi.org/10.1007/s40266-019-00700-w.
- El Khoudary S.R., Greendale G., Crawford S.L., Avis N.E., Brooks M.M., Thurston R.C. et al. The menopause transition and women's health at midlife: a progress report from the Study of Women's Health Across the Nation (SWAN). Menopause. 2019; 26(10): 1213-27. https://dx.doi.org/10.1097/GME.0000000000001424.
- Angelou K., Grigoriadis T., Diakosavvas M., Zacharakis D., Athanasiou S. The genitourinary syndrome of menopause: an overview of the recent data. Cureus. 2020; 12(4): e7586. https://dx.doi.org/10.7759/cureus.7586.
- Cagnacci A., Xholli A., Sclauzero M., Venier M., Palma F., Gambacciani M.; Writing Group of the ANGEL study. Vaginal atrophy across the menopausal age: results from the ANGEL study. Climacteric. 2019; 22(1): 85-9. https://dx.doi.org/10.1080/13697137.2018.1529748.
- Isaza P.G. Use of growth factors for vulvo/vaginal bio-stimulation. Surg. Technol. Int. 2019; 34: 269-73.
- Kasap B., Kasap Ş., Vatansever S., Kendirci R., Yılmaz O., Çalışır M. et al. Effects of adipose and bone marrow-derived mesenchymal stem cells on vaginal atrophy in a rat menopause model. Gene. 2019; 711: 143937. https://dx.doi.org/10.1016/j.gene.2019.06.027.
- Пищевой Живой Коллаген торговой марки Colla Gen. [Food Alive Collagen branded by Colla Gen (in Russian)]. https://collagen-pmt.ru/ pishchevoy-kollagen/
- Rosen R., Brown C., Heiman J., Leiblum S., Meston C., Shabsigh R. et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J. Sex Marital Ther. 2000; 26(2): 191-208. https://dx.doi.org/10.1080/ 009262300278597.
- Министерство здравоохранения Российской Федерации. Клинические рекомендации «Менопауза и климактерическое состояние у женщины». 2021. [Ministry of Health of the Russian Federation. Clinical guidelines "Menopause and menopause in a woman." 2021. (in Russian)].
- Nappi R.E., Palacios S., Bruyniks N., Particco M., Panay N.; EVES study investigators. The burden of vulvovaginal atrophy on women's daily living: implications on quality of life from a face-to-face real-life survey. Menopause. 2019; 26(5): 485-91. https://dx.doi.org/10.1097/GME.0000000000001260.
- Балан В.Е., Краснопольская К.В., Оразов М.Р., Токтар Л.Р., Тихомирова Е.В. Коллагенотерапия пациенток с генитоуринарным менопаузальным синдромом – новая возможность в арсенале врача. Российский вестник акушера-гинеколога. 2020; 20(4): 65 75. [Balan V.E., Krasnopol’skaya K.V., Orazov M.R., Toktar L.R., Tikhomirova E.V. Collagenotherapy for patients with genitourinary menopausal syndrome is a new opportunity in the doctor’s arsenal. Russian Bulletin of Obstetrician-Gynecologist. 2020; 20(4): 65-75. (in Russian)]. https:// dx.doi.org/10.17116/rosakush20202004165.
Supplementary files
